Jip Groen

Mr. Jip Groen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2025 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
JGJip Groen
Jip Groen
MGMorris Gordon
Morris Gordon
ACAshish Chogle
Ashish Chogle
MBMarc Benninga
Marc Benninga
RBRachel Borlack
Rachel Borlack
MSMiguel Saps
Miguel Saps
Objectives: Abdominal pain related disorders of gut–brain interaction (AP‐DGBIs) such as irritable bowel syndrome (IBS) and functional abdominal pain‐not otherwise specified (FAP) are common conditions in children, significantly impacting quality of life. This treatment guideline for IBS and FAP in children of 4–18 years is a collaborative effort of the European and North American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN). We aim to comprehensively review the current evidence on treatment options and offer evidence‐based recommendations with utility across all treatment settings worldwide, as well as to provide methodological directions for future research.Methods: The guideline development followed the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach, which is in accordance with the GRADE handbook and supported by the World Health Organization. The Guideline Development Group (GDG) comprised clinical experts, representing ESPGHAN, NASPGHAN, and Cochrane. Individual members have put forward a final consensus list of treatment options, which were then translated into “patient, intervention, comparison, outcome” (PICO) format options. Prospective agreement on decision thresholds for efficacy and safety outcomes was reached through a Delphi process among the GDG to support GRADEing of the literature. Consensus voting was used to finalize recommendations, and a treatment algorithm was developed.Results: Systematic literature searches for this output identified 86 original randomized controlled trials assessing treatment of IBS and FAP. Consensus was reached for 25 GRADEd recommendations. Ten best practice statements were formulated, and guidance for future research methodology was proposed.Conclusion: This guideline represents the first collaborative output of ESPGHAN and NASPGHAN on treatment options for AP‐DGBIs. Systematic review of the evidence has exposed major evidence gaps for the treatment of these disorders and incentivizes large pediatric trials, particularly on treatment options for which, to date, no evidence exists.

1 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
JGJip Groen
Jip Groen
MKMartijn van der Kuip
Martijn van der Kuip
DBDries Budding
Dries Budding
MBMartine P. Bos
Martine P. Bos
MBMarc Alexander Benninga
Marc Alexander Benninga
TMTim de Meij
Tim de Meij
Managing neonatal sepsis is challenging due to nonspecific clinical signs, hematological markers with poor accuracy, and a lengthy turnaround time for the identification of microorganisms. Delaying the initiation of antibiotics in truly infected infants can lead to severe morbidity and mortality. Therefore, decisions regarding empiric antibiotic treatment are risk stratified, which exposes many uninfected infants to antibiotics. This causes gut microbiota perturbation, unnecessary hospital admissions, and the generation of multi-resistant organisms. High-speed diagnostic assays could expedite discontinuation or avert the initiation of antibiotics in uninfected infants. This study will evaluate the diagnostic performance of molecular culture (MC), a rapid broad-range PCR-based bacterial profiling technique, for diagnosing neonatal sepsis in infants below 90 days old. A multi-center prospective observational cohort study will include infants evaluated for early and late-onset sepsis. Routine evaluation for suspected sepsis includes microbiological cultures of blood. Additionally, blood for MC will be collected. For early-onset sepsis, umbilical cord blood may be used alternatively. Primary outcome is the agreement between MC and conventional blood culture results. Secondary outcome is the agreement of both assays with clinical sepsis using four different, commonly used definitions. Faster diagnostic pathways for sepsis may reduce antibiotic exposure time. Broad-range molecular assays may identify pathogens undetectable by conventional methods. Employment of umbilical cord blood samples for early-onset sepsis diagnosis can resolve challenges in collecting adequate blood volume and could further expedite treatment decisions.

30 April 2026 in BMJ Paediatrics Open
Verified
Journal Article
Open access
JGJip Groen
Jip Groen
MKMartijn van der Kuip
Martijn van der Kuip
MBMarc A Benninga
Marc A Benninga
TMTim de Meij
Tim de Meij
HNHendrik Niemarkt
Hendrik Niemarkt